ClinicalTrials.gg
CompletedNCT01485640Updated Nov 4, 2016Results posted

Lurasidone Extended Use Study

A Phase 3 interventional study of Lurasidone in Schizophrenia and Bipolar Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 46 sites in 12 countries. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
19th of 39
162 · median 149
Started
2011
with 2 others
Phase 3
18 of 39
none open now
Registered
18th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 19th largest by enrollment, is one of 3 that started in 2011, is one of 18 in phase 3, and was the 18th registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.

03

Conditions studied

  • Schizophrenia
  • Bipolar Disorder

Keywords

  • Schizophrenia
  • bipolar disorder
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject or legal guardian provides written . For eligible subjects under age 18, verbal assent is also required.
  • The subject has completed the extension phase of a prior lurasidone clinical study. Eligible subjects may enroll into this continuation study directly (or within 10 days) after completing the extension phase of a prior lurasidone clinical study. Subjects that have completed an extension study prior to the initiation of this protocol at the study site, may participate in this study up to 3 months after completion of the extension phase of the prior lurasidone study.
  • The subject is judged by the Investigator to be suitable for participation in a clinical study involving open-label lurasidone treatment and is able to comply with the protocol.
  • The subject, in the Investigator's judgment, may benefit from continued treatment with lurasidone

Exclusion criteria

Exclusion Criteria:

  • The subject is considered by the Investigator, to be at imminent risk for homicidal or suicidal behavior.
  • The subject resides in a country where lurasidone has been approved for any indication.
  • The subject is currently enrolled in any other study.
  • The subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Lurasidone flexibly dosed

    Drug: Lurasidone

Interventions

  • Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs

    Primary Safety assessments included spontaneous adverse event (AE) and serious adverse events (SAEs) monitoring.

    Time frame: 18 months

Secondary outcomes

  1. Change From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S

    The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

    Time frame: 18 months

07

Results

Posted Mar 11, 2015

Participant flow

Participant flow — Overall Study
MilestoneLurasidone
Started162
Completed40
Not completed122
Withdrew: Adverse event10
Withdrew: Lack of efficacy2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject14
Withdrew: Terminated by sponsor95

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs

Primary Safety assessments included spontaneous adverse event (AE) and serious adverse events (SAEs) monitoring.

Time frame:
18 months
Reported as:
Number · participants
Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs
participantsLurasidone
Subject with at least on treatment emergent AE63
Subject with at least one treatment emergent SAE7
Subjects discontinued due to TEAE10
SecondaryChange From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S

The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

Time frame:
18 months
Reported as:
Mean · units on a scale
Change From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S
units on a scaleLurasidone
Change From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S-0.18 ± 0.877

Adverse events

Collected over 18 Months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—7/162 (4.3%)40/162 (24.7%)
Most frequent serious events
Most frequent serious events
EventLurasidone
ManiaPsychiatric disorders2/162
Pilonidal cystInfections and infestations1/162
Foot fractureInjury, poisoning and procedural complications1/162
DepressionPsychiatric disorders1/162
Depression suicidalPsychiatric disorders1/162
Schizophrenia, paranoid typePsychiatric disorders1/162
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLurasidone
HeadacheNervous system disorders9/162
DiarrhoeaGastrointestinal disorders6/162
InfluenzaInfections and infestations6/162
NasopharyngitisInfections and infestations6/162
VomitingGastrointestinal disorders5/162
AnxietyPsychiatric disorders5/162
InsomniaPsychiatric disorders5/162
NauseaGastrointestinal disorders4/162
Viral upper respiratory tract infectionInfections and infestations4/162
Hepatic enzyme increaseInvestigations4/162

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lurasidone
<=18 years1
Between 18 and 65 years159
>=65 years2
Age, Continuous
Age, Continuous(years)Lurasidone
Mean41.3 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone
Female77
Male85
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone
American Indian or Alaska Native0
Asian32
Native Hawaiian or Other Pacific Islander0
Black or African American5
White105
More than one race0
Unknown or Not Reported20
Region of Enrollment
Region of Enrollment(participants)Lurasidone
Serbia6
France6
Czech Republic25
Slovakia17
Canada3
Ukraine11
Romania2
Lithuania8
Russian Federation20
South Africa26
Colombia6
India32
08

Study locations

46 sites
  • Okanagan Clinical Trials
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA Investigations
    Barranquilla, Colombia
  • E.S.E. Hospital Mental de Antioquia
    Bello, Colombia
  • CISNE - UIC Campo Abierto
    Bogota, Colombia
  • Psychiatricka ambulance
    Brno-mesto, 602 00, Czech Republic
  • Vojenska nemocnice Olomouc
    Olomouc, 711 11, Czech Republic
  • Clintrial, s.r.o.
    Praha, 10 100 00, Czech Republic
  • Psychiatry Trial s.r.o.
    Praha, 158 00, Czech Republic
  • Medical Services Prague s.r.o.
    Praha, 6 160 00, Czech Republic
  • Zans Ritter, Marcel
    Orvault, 44700, France
  • Hôpital Chalucet, Centre hospitalier intercommunal de Toulon la Seyne sur mer (CHITS)
    Toulun, 83000, France
  • Brain Mind Behavior Neuroscience Research Institute
    Vishakhapatnam, Andh Prad 530002, India
  • Vijayawada Institute of Mental Health and Neurosciences
    Vijayawada, Andhra Pradesh 520002, India
  • Samvedna Hospitals
    Ahmedabad, Gujarat 380006, India
  • Seth K M School of P G Medicine & Research
    Ahmedabad, Gujarat 380006, India
  • Mental Health Treatment Rehabililitation Foundation Dept. of Psychiatry
    Ahmedabad, Gujarat 380013, India
  • Hatkesh Healthcare Foundation
    Junagadh, Gujarat 362001, India
  • Brij Psychiatry Hospital & Muskaan Research Centre
    Vadodara, Gujarat 390001, India
  • Shanti Nursing Home
    Aurangabad, Maharashtra 431005, India
  • Dr. Tambi's Neuropsychiatry Center
    Jaipur, Rajaasthan 302017, India
  • R.K. Yadav Memorial Mental Health & De-Addiction Hospital Psychiatry
    Jaipur, Rajasthan 302021, India
  • Mahendru Psychiatric Centre
    Kanpur, 208005, India
  • Neuromeda JSC
    Kaunas, 50185, Lithuania
  • JSC Neuromeda
    Kaunas, LT-50185, Lithuania
  • Seskines Outpatient Clinic, Public Institution
    Vilnius, 07156, Lithuania
  • Spitalul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca, 400012, Romania
  • Spitalul Clinic de Neuropsihiatrie Craiova
    Craiova, 200620, Romania
  • Regional Government Institution (RGI) 'Lipetsk Regional Psychoneurology Hospital'
    Lipetsk, 398007, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7"), at Daycare Facility #1
    St. Petersburg, 19005, Russian Federation
  • St. Petersburg State Government Healthcare Institution "City Psychiatric Hospital #4" (St. Petersburg Insane Asylum Distributor)
    St. Petersburg, 191119, Russian Federation
  • St. Petersburg State Healthcare Institution (SPbSHI) "City Psychiatric Hospital #6"
    St. Petersburg, 191167, Russian Federation
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • Clinical Centre Nis, Clinic for mental health protection
    Nis, 18000, Serbia
  • Psychiatricka ambulancia Mentum s.r.o.
    Bratislava, 82007, Slovakia
  • PsychoLine s.r.o. Psychiatricka ambulancia
    Rimavska Sobota, 97901, Slovakia
  • Centrum zdravia R.B.K. s.r.o. Psychiatricka ambulancia
    Svidnik, 08901, Slovakia
  • Pro mente sana s.r.o. Psychiaricka ambulancia
    Trencin, 91101, Slovakia
  • Dey Clinic
    Pretoria, Gauteng 181, South Africa
  • Cape Trial Centre
    Tygervalley, Western Cape 7530, South Africa
  • Denmar Hospital Consulting Rooms
    Pretoria, 0081, South Africa
  • Kherson Regional Psychiatric Hospital
    Kherson, Vil Stepanivka 73488, Ukraine
  • Dnipropetrovsk Regional Clinical Hospital named Mechnikov
    Dnipropetrovsk, 49005, Ukraine
  • Regional Clinical Psychiatric Hospital, Dept #11
    Donetsk, 83037, Ukraine
  • Institute of Neurology, Psychiatry and Narcology, NAMS of Ukraine
    Khardov, 61068, Ukraine
  • Crimean republican Clinical Psychiatric Hospital
    Simferopol, Ukraine
  • Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21
    Vinnitsia, 21018, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2011
First posted
Dec 5, 2011
Start
Jun 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 11, 2015
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01485640
Responsible party
Sponsor
First posted
Dec 5, 2011
Start date
Jun 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 11, 2015
Last update
Nov 4, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion